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Editorial
With broad usage of direct acting antivi-
rals (DAAs) the global epidemics of hepati-
tis C will probably come to an end in next
20 years.1,2 The price of DAAs is still high
in European countries and in USA, but it is
plausible to assume that the availability of
generic drugs will make the treatment pos-
sible for the majority of diagnosed patients.
So we will be able to eliminate the virus
without really understanding the pathophys-
iology of chronic infection, fibrogenesis
and carcinogenesis. Substantial number of
treated patients will therefore have to be
followed up for cirrhosis and hepatocellular
carcinoma. 
There is growing evidence that liver
non-parenchymal cells, specifically liver
sinusoidal endothelial cells (LSEC) and
Kupffer cells (KC), may play key roles in
regulating immune responses and facilitat-
ing tolerance induction.3,4 Previously pub-
lished gene expression analyses have
revealed new disease specific changes in
gene expression, identified potential bio-
markers of HCV infection and suggested a
new mechanism of host cell-virus interac-
tion that results in viral particle assembly,
secretion and infectivity.5-9 In vitro HCV
JFH-1 infection studies have shown differ-
ent gene expression repertoires; unlike
macrophages that demonstrated a broad
increase in IL1β and NFκB-responsive
proinflammatory cytokines and
chemokines, transcriptome changes in
hepatocytes enable the replicative infection,
while LSEC favor the transcription of
immunomodulators that can silence the
inflammatory reaction and favor fibrogene-
sis.5,7-10 Multiple strategies by which HCV
evades the surveillance of the host immune
system are proposed and yet to be
explained.
These in vitro cell cultures studies sug-
gested the connection of immune sema-
phorins with HCV infection. Semaphorins
are a class of secreted and membrane-bound
proteins that regulate key cellular functions
involved in cell-cell communication. The
importance of semaphorins and plexins has
been emphasized by their discovery in
many organ systems including the nervous,
epithelial, and immune systems as well as
diverse cell processes including angiogene-
sis, embryogenesis and cancer.11,12 Studies
of plexins and semaphorins have revealed
that several members of these families are
involved in a series of immune cell interac-
tions, which ultimately influence the out-
come of the immune response and substan-
tially influence the level of inflamma-
tion.11,12 Interestingly, semaphorins play the
opposite roles in innate versus adaptive
immune response, amplifying inflammation
while dampening T-cell proliferation and
activation.11,13,14 Although immune sema-
phorins are crucial to various phases of the
immune response, so far semaphorins have
not been linked with HCV infection. 
Previously mentioned gene expression
studies have linked several semaphorins
with HCV infection: SEMA3C was shown
to increase the production/secretion of sev-
eral extracellular matrix components
(fibronectin, elastin, collagen) and promot-
ing factors (CTGF, IL6 and TGF-β1), and
the expression of SEMA3C correlated posi-
tively with the degree of fibrosis in adipose
tissue;15 SEMA6B and SEMA6D might
bind to and activate dendritic cells and
increase type I interferon production.16
We have been able to show in our
Croatian Science Foundation project
Infectomics study of the human liver non-
parenchymal cells in chronic hepatitis C
that serum concentrations of secreted sema-
phorins are higher in HCV infected patients,
and their serum concentration correlate with
the degree of liver fibrosis.17
Immunohistochemistry in transplanted liv-
ers revealed the absence of semaphorins in
healthy livers in comparison with strong
positivity in LSEC and KC in explanted cir-
rhotic HCV positive livers (Vince A.,
unpublished data). Furthermore, results of
that research imply the usage of sema-
phorins as predictive markers of liver cir-
rhosis, stronger then APRI score and FIB4
test.17 These results provide first evidence
that semaphorins are involved in immune
response to chronic HCV infection. This
might have import clinical implications as
well, since their concentration correlates
with the extent of liver disease, they might
be considered as new biomarkers of liver
fibrogenesis. 
Although the serum concentration of
semaphorins in people who develop hepato-
cellular carcinoma should be evaluated fur-
ther, recent studies showed that sema-
phorins that restrict cell migration and
angiogenesis are often downregulated,
while those that support cancer progression
and metastatic spreading are frequently
upregulated in other cancers.18 It was also
shown that blocking these molecules effec-
tively reduce tumor angiogenesis and
metastatic spreading in preclinical trials in
mice.18-20
These data validate the identification of
semaphorin signals as a potential biomarker
of infection and fibrosis stage in chronic
viral hepatitis and promising therapeutic
targets in liver cancer.
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